Temozolomide in malignant gliomas: current use and future targets

@article{Villano2009TemozolomideIM,
  title={Temozolomide in malignant gliomas: current use and future targets},
  author={John L Villano and Tara E. Seery and Linda R. Bressler},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={64},
  pages={647-655}
}
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance. 

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 77 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 62 references

A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12 ISRCTN83176944)

  • SM Lee, M Brada, S Stenning, L Thompson, R Gabe
  • Ann Oncol 19:viii2 (LBA
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…